Document is current
Any future updates will be listed below
-
Authors
Carlino, Matteo S
Liu, Jia
Silk, Ann W
Muzaffar, Jameel
Dizdar, Omer
Castonguay, Vincent
Miller, Wilson
Koyfman, Shlomo
Bhatia, Aarti
Suttner, Leah
Gozman, Alex
Groisberg, Roman
Nguyen, Bella
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06036836 at ClinicalTrials.govnct06036836 at ClinicalTrials.govDocuments that mention this clinical trial
308 A randomized, double-blind, phase 2 study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs pembrolizumab plus lenvatinib in patients with previously treated mismatch repair-proficient advanced endometrial cancer
https://doi.org/10.1136/ijgc-2024-esgo.1104
1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 study
https://doi.org/10.1136/jitc-2025-sitc2025.1305
Documents that mention this clinical trial
308 A randomized, double-blind, phase 2 study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs pembrolizumab plus lenvatinib in patients with previously treated mismatch repair-proficient advanced endometrial cancer
https://doi.org/10.1136/ijgc-2024-esgo.1104
1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 study
https://doi.org/10.1136/jitc-2025-sitc2025.1305
- License Information
